$411M
The Series A round was co-led by Forbion and General Atlantic to support clinical trials and portfolio expansion.
"People living with obesity and its complications deserve better options at each stage of their treatment journey. These include oral therapies with less frequent dosing regimens, which have the potential for improved efficacy and tolerability, and innovative combination therapies for healthier weight loss and—equally importantly—maintenance of metabolically healthy weight. We created Verdiva Bio to accelerate the development of differentiated medicines that address these significant unmet medical needs."
